Author

M. D. Dun

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. Mannan· 4 shared H. C. Murray· 4 shared N. M. Verrills· 4 shared A. M. Douglas· 3 shared B. Nixon· 3 shared D. A. Skerrett-Byrne· 3 shared E. R. Jackson· 3 shared I. J. Findlay· 3 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Mannan

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal.

D. R. Bond, S. M. Burnard, K. Uddipto, K. V. Hunt, B. M. Harvey, L. Steffens Reinhardt, C. Lawlor-O'Neill, E. A. Roper, S. Humphries, H. C. Murray, A. Mannan, M. D. Dun, C. de Bock, N. A. Bowden, A. K. Enjeti, , H. J. Lee

This study shows that hypomethylating agents induce epigenetic and transcriptional heterogeneity in AML cells, with some cells retaining methylation and showing increased self-renewal, and identifies statins as a potential co-treatment to enhance HMA efficacy.

bioRxiv · Jan 30, 2024Cancer Biology

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

R. J. Duchatel, E. R. Jackson, S. G. Parackal, C. Sun, P. Daniel, A. Mannan, I. J. Findlay, D. Staudt, Z. P. Germon, S. Laternser, D. Kiltschewskij, P. S. Kearney, M. F. B. Jamaluddin, A. M. Douglas, T. Beitaki, , M. D. Dun

This study identifies PI3K/mTOR as a targetable genetic dependency in DIPG and demonstrates that combining paxalisib with metformin improves survival in xenograft models.

bioRxiv · Apr 17, 2023Cancer Biology

High-Throughput Global Phosphoproteomic Profiling Using Phospho Heavy-Labeled-Spiketide FAIMS Stepped-CV DDA (pHASED)

D. E. Staudt, H. C. Murray, D. A. Skerrett-Byrne, N. D. Smith, M. F. Jamaluddin, R. G. S. Kahl, R. J. Duchatel, Z. Germon, T. McLachlan, E. R. Jackson, I. J. Findlay, P. S. Kearney, A. Mannan, H. P. McEwen, A. M. Douglas, , M. D. Dun

This paper introduces a new phosphoproteomics protocol, pHASED, which reduces sample preparation time and increases phosphoproteomic coverage compared to traditional methods, revealing potential therapeutic targets in AML.

bioRxiv · Apr 22, 2022 · PreprintBiochemistry

Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies

Z. P. Germon, J. R. Sillar, A. Mannan, R. J. Duchatel, D. Staudt, H. C. Murray, I. J. Findlay, E. R. Jackson, H. P. McEwen, A. M. Douglas, T. Mclachlan, J. E. Schjenken, D. A. Skerrett-Byrne, H. Huang, M. N. Melo-Braga, , M. D. Dun

This study identifies the Rac-NOX2 complex as a driver of redox signaling in FLT3-mutant AML, showing that inhibiting NOX2 reduces key signaling pathways and enhances response to FLT3 inhibitors.

bioRxiv · Mar 9, 2022 · PreprintCancer Biology